Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$20.40

-0.62 (-2.95%)

, IPSEY

Ipsen

$0.00

(0.00%)

05:29
05/17/18
05/17
05:29
05/17/18
05:29

Exelixis partner Ipsen announces EC approval of Cabometyx

Exelixis (EXEL) announced that its partner Ipsen (IPSEY) received approval from the European Commission, or EC, for Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma, or RCC, in the European Union. Under the terms of the Collaboration and License Agreement with Ipsen, Exelixis will receive a milestone payment of $50 million for the EC approval, of which approximately $46 million was recognized as collaboration revenue in the first quarter of 2018. The payment will be made by Ipsen within the next 70 days.

EXEL

Exelixis

$20.40

-0.62 (-2.95%)

IPSEY

Ipsen

$0.00

(0.00%)

  • 21

    May

  • 12

    Jun

EXEL Exelixis
$20.40

-0.62 (-2.95%)

05/10/18
PIPR
05/10/18
NO CHANGE
Target $29
PIPR
Overweight
Exelixis price target lowered to $29 from $33 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Exelixis (EXEL) to $29 from $33 after partner Roche (RHHBY) reported the Phase 3 IMblaze370 trial in microsatellite stable colorectal cancer patients did not meet its overall survival primary endpoint. However, the data do not impact two ongoing Phase 3 trials of cobimetinib and Tecentriq in BRAF-mutant melanoma, said Tenthoff, who keeps an Overweight rating on Exelixis shares.
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.
04/11/18
WBLR
04/11/18
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis after 28% pullback
William Blair analyst Andy Hsieh says he's an "aggressive" buyer of Exelixis with the stock down 28% since the Q4 earnings call on February 28. The previously announced Merck-Eisai collaboration agreement to jointly develop and commercialize Lenvima could serve as a comp to Exelixis's cabozantinib franchise, Hsieh tells investors in a research note. Eisai ascribes a value of roughly $7.9B for the Lenvima franchise, which equates to $26.66 per share for Exelixis, the analyst writes. With Exelixis trading at $6.3B in market cap or $5.8B in enterprise value, the current valuation does not account for the full potential of the cabozantinib franchise and does not include Cotellic, which is in three Phase III studies and being investigated in four oncology indications, Hsieh argues. He keeps an Outperform rating on the shares and believes the Merck-Eisai Deal highlights a "significant valuation disconnect."
04/10/18
RBCM
04/10/18
NO CHANGE
RBCM
Top Pick
Exelixis selloff yesterday a buying opportunity, says RBC Capital
RBC Capital analyst Kennen MacKay attributes yesterday's late-date weakness in shares of Exelixis (EXEL) to the clinicaltrials.gov update for Roche's (RHHBY) first-line metastatic colorectal cancer maintenance study indicating that recruitment has been suspended. The study is assessing "Cotezo," a combination of Exelixis/Roche's Cotellic and Roche's Tecentriq. The analyst says his correspondence with Exelixis management highlights that this is a temporary halt on recruitment only. MacKay recommends buying Exelixis on the weakness and remains bullish on the IMblaze370 trial.
IPSEY Ipsen
$0.00

(0.00%)

09/19/17
SOCG
09/19/17
UPGRADE
SOCG
Buy
Ipsen upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Delphine Le Louet upgraded Ipsen to Buy with a price target of EUR 126.

TODAY'S FREE FLY STORIES

AVMXY

Avita Medical

$0.00

(0.00%)

20:06
11/15/18
11/15
20:06
11/15/18
20:06
Hot Stocks
Avita Medical to hire U.S. sales team to support national launch of Recell »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDXAY

Sodexo

$0.00

(0.00%)

20:05
11/15/18
11/15
20:05
11/15/18
20:05
Downgrade
Sodexo rating change  »

Sodexo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$38.83

0.91 (2.40%)

20:01
11/15/18
11/15
20:01
11/15/18
20:01
Hot Stocks
Cathay General raises quarterly dividend to 31c from 24c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SUPV

Grupo Supervielle

$8.50

0.42 (5.20%)

19:56
11/15/18
11/15
19:56
11/15/18
19:56
Downgrade
Grupo Supervielle rating change  »

Grupo Supervielle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAAP

Corporacion America Airport

$8.37

0.63 (8.14%)

19:52
11/15/18
11/15
19:52
11/15/18
19:52
Hot Stocks
Corporacion America Airport reports October traffic up 4.5% »

Corporacion America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$348.37

4.3 (1.25%)

19:43
11/15/18
11/15
19:43
11/15/18
19:43
Periodicals
Tesla aims for Model 3 output of 7K units per week in two weeks, Electrek says »

Tesla has looked to ramp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

AIV

Aimco

$44.65

-0.46 (-1.02%)

19:26
11/15/18
11/15
19:26
11/15/18
19:26
Hot Stocks
Aimco says California fires have not caused material damage to company »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$239.93

4.83 (2.05%)

19:19
11/15/18
11/15
19:19
11/15/18
19:19
Initiation
Adobe initiated  »

Nomura starts Adobe with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPWR

Ideal Power

$0.39

-0.1505 (-27.87%)

19:16
11/15/18
11/15
19:16
11/15/18
19:16
Downgrade
Ideal Power rating change  »

Ideal Power downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SONO

Sonos

$14.14

0.17 (1.22%)

, SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

19:09
11/15/18
11/15
19:09
11/15/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sonos…

SONO

Sonos

$14.14

0.17 (1.22%)

SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

BGCP

BGC Partners

$10.66

0.24 (2.30%)

SALT

Scorpio Bulkers

$5.71

0.115 (2.06%)

ESEA

Euroseas

$1.65

-0.11 (-6.25%)

NVDA

Nvidia

$202.65

5.43 (2.75%)

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

JWN

Nordstrom

$58.97

-2.125 (-3.48%)

AMAT

Applied Materials

$35.03

1.44 (4.29%)

HTHT

Huazhu Group

$28.59

0.64 (2.29%)

SQ

Square

$73.59

3.74 (5.35%)

NGVC

Natural Grocers

$16.66

0.06 (0.36%)

MCF

Contango Oil & Gas

$4.50

-0.19 (-4.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

  • 12

    Dec

  • 18

    Dec

DOMO

Domo

$15.96

0.47 (3.03%)

19:04
11/15/18
11/15
19:04
11/15/18
19:04
Hot Stocks
Domo unveils new product suite »

Domo, provider of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCH

PotlatchDeltic

$36.71

-0.31 (-0.84%)

19:01
11/15/18
11/15
19:01
11/15/18
19:01
Hot Stocks
PotlatchDeltic to pay special dividend of about $3.54 per share »

PotlatchDeltic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

18:54
11/15/18
11/15
18:54
11/15/18
18:54
Periodicals
Senator to ask Facebook about report on treatment of critics, Reuters says »

Senator Amy Klobuchar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ALRM

Alarm.com

$48.81

0.82 (1.71%)

18:45
11/15/18
11/15
18:45
11/15/18
18:45
Hot Stocks
Alarm.com CEO sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 05

    Dec

LAUR

Laureate Education

$14.45

0.3 (2.12%)

18:31
11/15/18
11/15
18:31
11/15/18
18:31
Syndicate
Laureate Education 12.25M share Secondary priced at $14.00 »

Credit Suisse, Barclays,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:28
11/15/18
11/15
18:28
11/15/18
18:28
Periodicals
CPUC doesn't want PG&E to go into bankruptcy, Bloomberg says »

A California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

18:24
11/15/18
11/15
18:24
11/15/18
18:24
Periodicals
SEC investigating a company's $50M cryptocurrency sale, WSJ reports »

The SEC is investigating…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:23
11/15/18
11/15
18:23
11/15/18
18:23
Hot Stocks
PG&E cut to Baa3 from Baa2 by Moody's, could be cut further »

Moody's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMB

Limbach Holding

$8.31

-0.14 (-1.66%)

18:10
11/15/18
11/15
18:10
11/15/18
18:10
Hot Stocks
Limbach Holding lowers FY18 EBITDA view to $8M-$10M from $18M-$20M »

Backs FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NVDA

Nvidia

$202.65

5.43 (2.75%)

18:08
11/15/18
11/15
18:08
11/15/18
18:08
Hot Stocks
Nvidia CEO says the ramp of Turing GPU is 'going great' »

Says Turing represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

BDRBF

Bombardier

$0.00

(0.00%)

18:06
11/15/18
11/15
18:06
11/15/18
18:06
Hot Stocks
Bombardier intends to fully cooperate with AMF review »

Bombardier said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NVDA

Nvidia

$202.65

5.43 (2.75%)

18:04
11/15/18
11/15
18:04
11/15/18
18:04
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

NVDA

Nvidia

$202.65

5.43 (2.75%)

18:01
11/15/18
11/15
18:01
11/15/18
18:01
Hot Stocks
Nvidia CEO says came into Q3 with excess inventory from crypto overhang »

Says the decline in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

TDW

Tidewater

$25.71

1.22 (4.98%)

17:52
11/15/18
11/15
17:52
11/15/18
17:52
Hot Stocks
Tidewater CFO Quinn Fanning steps down, succeeded by Gulfmark CEO Quintin Kneen »

Tidewater CFO Quinn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

17:52
11/15/18
11/15
17:52
11/15/18
17:52
Hot Stocks
Nvidia CEO expects to continue seeing demand in data center business »

Says because CPUs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.